Hangzhou Tigermed Consulting Co., Ltd.
HNGZY · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $25 | $26 | $69 | $70 |
| - Cash | $2 | $7 | $8 | $9 |
| + Debt | $3 | $3 | $3 | $1 |
| Enterprise Value | $26 | $21 | $64 | $63 |
| Revenue | $7 | $7 | $7 | $5 |
| % Growth | -10.6% | 4.2% | 35.9% | – |
| Gross Profit | $2 | $3 | $3 | $2 |
| % Margin | 34% | 38.6% | 39.6% | 43.6% |
| EBITDA | $1 | $3 | $3 | $4 |
| % Margin | 17.1% | 38.5% | 41.7% | 74.7% |
| Net Income | $0 | $2 | $2 | $3 |
| % Margin | 6.1% | 27.4% | 28.3% | 55.1% |
| EPS Diluted | 0.47 | 2.34 | 2.32 | 3.3 |
| % Growth | -79.9% | 0.9% | -29.7% | – |
| Operating Cash Flow | $1 | $1 | $1 | $1 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $1 | $1 | $1 | $1 |